评估实时电磁追踪下降低计划靶区边界对低危和中危前列腺癌患者的潜在获益
这项前瞻性非随机试验对31例低危和中危前列腺癌患者使用Calypso系统行分次内靶区定位并将计划靶区边界各方向缩减至2 mm,分析1333次分次的移动、中断和剂量学数据并随访生活质量至24个月;结果显示日常治疗平均10分钟,信标移动超过3 mm的时间仅占1.76%,6个月时扩展前列腺癌指数复合评分变化小于ProtecT对照组,但12和24个月肠道和泌尿领域无显著差异。
要点
- 31例患者计划靶区边界各方向缩减至2 mm,共分析1333次分次。
- 信标移动超过3 mm的时间平均仅占1.76%,治疗中断平均34.2秒。
- 6个月时扩展前列腺癌指数复合评分变化小于ProtecT对照组,12和24个月肠道和泌尿领域无显著差异。
核心结论
- 数据证实并支持Calypso追踪联合调强放疗可靠地使日常治疗干扰和治疗总时间最小化,计划靶区超出3 mm边界的时间小于2%。
- 使用3 mm计划靶区边界可提供足够的剂量学覆盖,同时最小化泌尿生殖和胃肠道毒性。
研究设计与样本
- 前瞻性非随机试验,使用Calypso定位系统对31例前列腺癌患者行分次内靶区定位,计划靶区边界各方向缩减至2 mm。
- 共分析1333次分次的前列腺移动、暂停与中断及剂量学数据,并在基线、治疗期间及治疗后至24个月追踪生活质量评分。
主要发现
- 日常治疗平均时间为10分钟,96.1%的治疗落在20分钟治疗时间窗标准内。
- 活跃治疗期间信标移动超过3 mm的时间平均仅占1.76%。
- 治疗中断平均长度为34.2秒,平均每3.39次分次发生1次中断。
- 前列腺位移或偏移在头或脚方向最大(分别为0.11 mm和0.09 mm)以及前或后方向(分别为0.07 mm和0.13 mm),其次为左或右方向(分别为0.05 mm和0.06 mm)。
- 6个月时患者扩展前列腺癌指数复合评分变化小于ProtecT对照组(短期发病率降低),但12和24个月肠道和泌尿领域无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study is to quantify and describe the feasibility, clinical outcomes, and patient-reported outcomes of reduced planning target volume (PTV) margins for prostate cancer treatment using real-time, continuous, intrafraction monitoring with implanted radiation frequency transponder beacons. METHODS AND MATERIALS: For this prospective, nonrandomized trial, the Calypso localization system was used for intrafraction target localization in 31 patients with a PTV margin reduced to 2 mm in all directions. A total of 1333 fractions were analyzed with respect to movement of the prostate, pauses and interruptions, and dosimetric data. Pre- and posttreatment quality-of-life scores were tracked at baseline, during treatment, and up to 24 months after treatment. RESULTS: The mean time of daily treatment was 10 minutes, with 96.1% of all treatments falling within a 20-minute treatment window standard. On average, beacon motion exceeded 3 mm during active treatment only 1.76% of the time. The average length of treatment interruption was 34.2 seconds, with an average of 1 interruption every 3.39 fractions. The displacement or excursion of the prostate was the greatest in the superior or inferior dimension (0.11 mm and 0.09 mm, respectively) and anterior or posterior dimension (0.07 mm and 0.13 mm, respectively), followed by the left or right dimension (0.05 mm and 0.06 mm, respectively). At 6 months, patients demonstrated a smaller change in Expanded Prostate Cancer Index Composite scores than the ProtecT comparator group (decreased short-term morbidity). However, in the Bowel and Urinary domains at 12 and 24 months, there was no significant difference. CONCLUSIONS: Our data confirm and support that the use of Calypso tracking with intensity modulated radiation therapy reliably provides minimal disruption to daily treatments and overall time of treatment, with the PTV only moving outside of a 3-mm margin < 2% of the time. The use of a 3-mm PTV margin provides adequate dosimetric coverage while minimizing genitourinary and gastrointestinal toxicity.
引用
- Chaurasia AR, Sun KJ, Premo C, et al. Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking. Adv Radiat Oncol. 2018. PMID: 30370364. doi:10.1016/j.adro.2018.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。